http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009232816-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af92759c928daeb7f0daabbb0499f059 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48 |
| filingDate | 2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cec336daa0c3c95fa0f3b79d672e059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccf6d091033fcee149911541a4bb4c7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9836c1c622d4411eeea0269ab1f4123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ff07039eba693d33ac427c80980cf0f |
| publicationDate | 2009-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009232816-A |
| titleOfInvention | Method for determining the effectiveness of anthracycline-based anticancer drug treatment and diagnostic support method for the effectiveness of anthracycline-based anticancer drug treatment |
| abstract | A novel anthracycline anticancer drug treatment evaluation method capable of more accurately determining the risk of cancer recurrence, and more accurate anthracycline anticancer drug treatment diagnosis. To provide a diagnostic support method for the effectiveness of a novel anthracycline anticancer drug treatment that can be supported According to the method for determining the risk of cancer recurrence according to the present invention, the expression levels and activity values of the first cyclin-dependent kinase (CDK) and the second CDK are obtained from a malignant tumor collected from a test cancer patient. A determination score is obtained based on (1), and the effectiveness of anthracycline-based anticancer drug treatment is determined based on the obtained determination score. Determination score = F (x) × G (y) (1) (Wherein x represents the first CDK specific activity and y represents the specific activity ratio) [Selection] Figure 9 |
| priorityDate | 2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 138.